Decreased peritherapeutic VEGF expression could be a predictor of responsiveness to first-line FOLFIRI plus bevacizumab in mCRC patients

Objective: Bevacizumab is the only anti-angiogenic agent approved in first-line therapy for metastatic colorectal cancer (mCRC). Although chemotherapy plus bevacizumab has led to improve outcomes for mCRC patients and is a common choice for first-line treatment of mCRC, previous research has establi...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Clin Exp Pathol
Autori principali: Tsai, Hsiang-Lin, Lin, Chih-Hung, Huang, Ching-Wen, Yang, I-Ping, Yeh, Yung-Sung, Hsu, Wen-Hung, Wu, Jeng-Yih, Kuo, Chao-Hung, Tseng, Fan-Ying, Wang, Jaw-Yuan
Natura: Artigo
Lingua:Inglês
Pubblicazione: e-Century Publishing Corporation 2015
Soggetti:
Original Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4396259/
https://ncbi.nlm.nih.gov/pubmed/25973082
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi